

CLEAN COPY OF THE CLAIMS AS AMENDED:

1. A peptide factor comprising amino acid residues 33 to 42 of murine epidermal growth factor peptide wherein:

a) the peptide factor is modified such that at least one murine epidermal growth factor tyrosine amino acid residue is substituted with a tyrosine analogue or at least one murine epidermal growth factor arginine amino acid residue is substituted with an arginine analogue; and

b) the peptide factor binds to laminin receptors.

2. The peptide factor of claim 1, wherein the N terminal of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety, the C terminal of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety or a murine epidermal growth factor cysteine residue thiol group is chemically modified by the addition of an amino acid capping moiety to the cysteine residue thiol group.

3. The peptide factor of claim 1, wherein the murine epidermal growth factor tyrosine residue is substituted by tetrahydroisoquinoline-3-carboxylic acid.

4. The peptide factor of claim 1, wherein the murine epidermal growth factor arginine residue is substituted by Citrulline.

5. A method of binding a laminin receptor as an antagonist comprising preparing a medicament comprising amino acid residues 33 to 42 of murine epidermal growth factor peptide wherein the peptide factor is modified such that at least one murine epidermal growth factor tyrosine amino acid residue is substituted with a tyrosine analogue or at least one murine epidermal growth factor arginine amino acid residue is substituted with an arginine analogue.

6. A method of binding a laminin receptor as an agonist comprising preparing a medicament comprising amino acid residues 33 to 42 of murine epidermal growth factor peptide wherein the peptide factor is modified such that at least one murine epidermal growth factor tyrosine amino acid residue is substituted with a tyrosine analogue or at least one murine epidermal growth factor arginine amino acid residue is substituted with an arginine analogue.

7. The method of claim 6, wherein the preparation of the medicament to bind a laminin receptor as an antagonist is used to treat endothelial cell wounding.

8. The method of claim 5, wherein the medicament to bind a laminin receptor as an antagonist is used to treat retinopathy of immaturity.

10 9. The peptide factor of claim 2, wherein the murine epidermal growth factor tyrosine residue is substituted by tetrahydroisoquinoline-3-carboxylic acid.

10. The peptide factor of claim 2, wherein the murine epidermal growth factor arginine residue is substituted by Citrulline.

11. The peptide factor of claim 2, wherein the murine epidermal growth factor
15 arginine residue is substituted by Citrulline.

12. The method of claim 5, wherein the N terminal of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety, the C terminal of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety or a murine epidermal growth factor
20 cysteine residue thiol group is chemically modified by the addition of an amino acid capping moiety to the cysteine residue thiol group.

13. The peptide factor of claim 12, wherein the murine epidermal growth factor tyrosine residue is substituted by tetrahydroisoquinoline-3-carboxylic acid.

14. The peptide factor of claim 12, wherein the murine epidermal growth factor arginine residue is substituted by Citrulline.

15. The method of claim 6, wherein the N terminal of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety, the C terminal of the murine epidermal growth factor amino acid residue is chemically modified by the addition of an amino acid capping moiety or a murine epidermal growth factor cysteine residue thiol group is chemically modified by the addition of an amino acid capping moiety to the cysteine residue thiol group.

16. The peptide factor of claim 15, wherein the murine epidermal growth factor tyrosine residue is substituted by tetrahydroisoquinoline-3-carboxylic acid.

17. The peptide factor of claim 15, wherein the murine epidermal growth factor arginine residue is substituted by Citrulline.

18. The method of claim 6, wherein the medicament to bind a laminin receptor as an agonist is used to treat retinopathy of immaturity.